G. Lou

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.

J. Ragaz, Jiong Wu, Bing-he Xu, 2015, The Lancet. Oncology.

The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer.

Q. Qu, Chengfang Shangguan, Chen Yang, 2021, Annals of palliative medicine.

Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer

Weiping Yang, W. Cao, Hao Li, 2009, Anti-cancer drugs.

[In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites].

Hao Li, Jinsong Jiang, Mei Geng, 2006, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Using detection of survivin‐expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer

Weiping Yang, W. Cao, Hao Li, 2011, Journal of surgical oncology.

The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer

Cheng Xu, K. Shen, Q. Qu, 2014, World Journal of Surgical Oncology.

A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.

W. Cao, Hao Li, Jinsong Jiang, 2009, Japanese journal of clinical oncology.

Clinical efficacy of palbociclib-based therapy in women with HR+/HER2- metastatic breast cancer in the real-world setting for Chinese women: a comparison with the IRIS study.

Q. Qu, C. Yang, M. Jiang, 2021, European review for medical and pharmacological sciences.

Using detection of survivin‐expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer

Weiping Yang, W. Cao, Hao Li, 2011, Journal of surgical oncology.